Best Exosome / Extracellular Vesicle CDMOs in India
· updated as new inspection, certificate, and trial data enters the platform
1
CDMOs tracked
1
Fully scored
Exosome and extracellular vesicle (EV) CDMOs manufacture next-generation delivery vehicles for RNA, proteins, and small molecules. As an emerging modality, the field is still standardizing cell-source, isolation, and potency methods.
Choosing an exosome CDMO turns on cell-source and culture scale, isolation method (TFF, chromatography), characterization, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
Last updated 2026-03-21. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
CLB
Clara Biotech
Indianapolis, IN
|
56.5 | — | — | — | 0 programs |
What to evaluate in a Exosome / Extracellular Vesicle CDMO
Cell source & scale
Confirm the producer cell source and whether culture is suspension-adapted for the volumes EV yields demand.
Isolation & purification
Isolation method (tangential-flow filtration, chromatography) drives yield, purity, and scalability. Ask how it performs at your target scale.
Characterization & potency
EV characterization (particle count, size, cargo, identity) and potency assays are still maturing — look for established, qualified methods.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
How do Indian CDMOs compare to Chinese and Korean alternatives on regulatory posture?
Indian CDMOs have historically led Asian peers in FDA inspection density — the FDA maintains a large inspection presence in India and Indian pharmaceutical exports to the US are among the highest globally. That translates to Indian CDMOs typically holding more FDA inspections on record than Chinese or Korean counterparts of comparable size. That said, inspection density is not the same as inspection outcome — the Signal Score's Quality Compliance pillar weights the classification (NAI/VAI/OAI), not just the count. Sponsors comparing Asian CDMOs should focus on the specific facility's inspection outcome record, not the country-aggregate; individual profile pages surface facility-level detail.
Which Indian CDMOs handle biologics and advanced therapy modalities?
India's CDMO base has traditionally been strongest in small molecules and oral solid dosage forms, but the biologics and advanced-therapy footprint has grown substantially. Notable capabilities exist across mAb manufacturing, biosimilar production, and increasingly viral vector + cell therapy. Cross-reference with modality pages to filter Indian CDMOs by capability class: biologics, mRNA, cell therapy, or the gene therapy umbrella. Individual CDMO profile pages surface the specific modality capabilities on file.
US and EU regulatory considerations for India-manufactured drug supply
Indian CDMOs supplying US markets need active FDA registrations and pre-approval inspection posture; the FDA has been publicly focused on Indian generic pharmaceutical quality for years, and inspection outcomes there materially affect commercial supply eligibility. EU supply requires EMA GMP certification with an EU-based Qualified Person for batch release, which for Indian-manufactured material requires either an EU-based CDMO partner for release or an in-house EU QP arrangement. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly, so Indian CDMOs with cross-jurisdictional posture rank higher on this pillar than domestic-market-only competitors.
Exosome / Extracellular Vesicle CDMOs — Frequently Asked Questions
Who are the top Exosome / Extracellular Vesicle CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Exosome / Extracellular Vesicle CDMOs include Clara Biotech. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
What should I look for in an exosome CDMO?
Confirm cell source and scalable culture, a robust isolation method (TFF or chromatography), qualified characterization and potency analytics, and a clean FDA and EMA/MHRA record.
Is exosome manufacturing standardized?
Not yet fully — cell-source, isolation, and potency methods are still maturing across the field, so a CDMO's specific platform and analytics maturity matter more than in established modalities.
Related modalities